ArticleMolecular medicine reports2021

MAPK4 silencing together with a PARP1 inhibitor as a combination therapy in triple‑negative breast cancer cells.

Xiaoqi Zeng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.